Bioventus Inc. (BVS)
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Bioventus Inc.
NASDAQ:BVSHealthcare · Medical - Devices
-10.39%$13.32
AH$13.32-0.04%vs close
Mkt Cap$910.17M
Float45.78M
O/S68.31M
Vol
$ Vol
RVOL
Inst Own78.9%
SI6.9%
Earnings
Dilution
Financials Summary
Revenue$568.09M
Net Income$22.73M
Total Assets$683.56M
Free Cash Flow$71.41M
Debt & Equity
Debt 63%
Equity 37%
Total Debt$311.35M
Total Equity$184.1M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in BVS's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$683.56M
Liabilities$455.11M
Accounts Receivable$128.3M
Accounts Payable$10.93M
Inventory$82.24M
PP&E (Net)$27.02M
Goodwill$7.46M
Intangible Assets$368.42M
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
| Revenue | $568.09M | $573.28M | $512.35M | $512.12M | $430.9M | $321.16M | $340.14M | $319.18M | $292.06M | $274.5M | $253.65M | $242.89M | $232.38M |
| YoY Growth | -0.9% | 11.9% | 0.0% | 18.8% | 34.2% | -5.6% | 6.6% | 9.3% | 6.4% | 8.2% | 4.4% | 4.5% | - |
| Cost of Revenue | $185.66M | $185.05M | $184.15M | $181.04M | $128.19M | $87.64M | $90.94M | $84.17M | $92.1M | $91.39M | $74.34M | $74.61M | $71.37M |
| Gross Profit | $382.43M | $388.23M | $328.19M | $331.08M | $302.71M | $233.52M | $249.21M | $235.01M | $199.96M | $183.11M | $179.31M | $168.28M | $161M |
| Gross Margin | 67.3% | 67.7% | 64.1% | 64.6% | 70.3% | 72.7% | 73.3% | 73.6% | 68.5% | 66.7% | 70.7% | 69.3% | 69.3% |
| Research and Development | $12.11M | $13.64M | $13.45M | $23.85M | $19.04M | $11.2M | $11.05M | $8.1M | $8.1M | $7.9M | $14.75M | $9.46M | $10.94M |
| Selling, General, and Administrative | $311.77M | $327.09M | $303.88M | $332.13M | $254.25M | $193.08M | $198.47M | $191.67M | $164.84M | $160.32M | $148.44M | $147.06M | $150.37M |
| Other | $0 | $59.47M | $92.59M | $142.33M | $17.35M | $8M | $8.48M | $9.74M | $0 | $0 | $10.57M | $8.97M | $7.76M |
| Total Operating Expenses | $323.88M | $400.2M | $409.92M | $498.31M | $290.64M | $212.28M | $218.01M | $209.5M | $172.94M | $168.22M | $173.76M | $165.49M | $169.07M |
| Operating Income (EBIT) | $58.55M | -$11.98M | -$81.72M | -$167.23M | $12.06M | $21.24M | $31.19M | $25.5M | $27.02M | $14.89M | -$16.59M | $20K | -$8.07M |
| Operating Margin | 10.3% | -2.1% | -16.0% | -32.7% | 2.8% | 6.6% | 9.2% | 8.0% | 9.3% | 5.4% | -6.5% | 0.0% | -3.5% |
| Interest Expense | $26.49M | $38.79M | $40.68M | $12.02M | $1.11M | $9.75M | $21.58M | $19.17M | $18.9M | $15.94M | $14.23M | $11.97M | $11.46M |
| Interest Income | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Income (Expense) | -$32.84M | -$37.15M | -$39.39M | -$21.79M | -$2.57M | -$5.32M | -$21.5M | -$19.4M | -$18.37M | -$20.54M | -$15.38M | -$11.37M | -$12.17M |
| Income Before Tax (EBT) | $25.71M | -$49.13M | -$121.11M | -$189.03M | $9.49M | $15.91M | $9.69M | $6.11M | $8.66M | -$5.65M | -$31.97M | -$11.35M | -$20.24M |
| Income Tax Expense | -$1.56M | -$5.29M | $85K | -$44.37M | -$1.97M | $1.19M | $1.58M | $1.66M | -$785K | $1.09M | $2.14M | $1.55M | $2.13M |
| Net Income | $22.73M | -$33.54M | -$156.23M | -$158.7M | $19.38M | $16.41M | $6.85M | -$12.21M | -$1.64M | -$17.95M | -$34.11M | -$12.9M | -$22.37M |
| Net Income Margin | 4.0% | -5.9% | -30.5% | -31.0% | 4.5% | 5.1% | 2.0% | -3.8% | -0.6% | -6.5% | -13.4% | -5.3% | -9.6% |
| Supplementary Data | |||||||||||||
| EPS | 0.34 | -0.52 | -2.49 | -2.59 | 0.43 | 0.44 | 0.12 | -0.22 | -0.13 | -0.41 | -0.69 | -0.30 | -0.47 |
| Diluted EPS | 0.33 | -0.52 | -2.49 | -2.59 | 0.43 | 0.44 | 0.12 | -0.22 | -0.13 | -0.41 | -0.69 | -0.30 | -0.40 |
| Weighted Average OS | 66.62M | 65.36M | 62.65M | 61.39M | 45.47M | 37.70M | 56.83M | 56.83M | 56.83M | 56.83M | 55.63M | 55.63M | 55.63M |
| EBITDA | $99.21M | $39.22M | -$23.07M | -$121.61M | $45.48M | $54.31M | $61.58M | $54.52M | $59.85M | $44.05M | $38.63M | $29.3M | $15.68M |
| EBITDA Margin | 17.5% | 6.8% | -4.5% | -23.7% | 10.6% | 16.9% | 18.1% | 17.1% | 20.5% | 16.0% | 15.2% | 12.1% | 6.7% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2018 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2018-12-31 | 2015-12-31 | 2014-12-31 |
| Assets | |||||||||
| Current Assets | |||||||||
| Cash and Cash Equivalents | $51.24M | $41.58M | $36.96M | $30.19M | $43.93M | $86.84M | $42.77M | $4.95M | $15.77M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $51.24M | $41.58M | $36.96M | $30.19M | $43.93M | $86.84M | $42.77M | $4.95M | $15.77M |
| Accounts Receivable | $128.3M | $127.39M | $122.79M | $136.29M | $124.96M | $88.28M | $73.04M | $54.51M | $47.08M |
| Inventory | $82.24M | $92.47M | $91.33M | $84.77M | $61.69M | $29.12M | $27.4M | $35.18M | $26.67M |
| Other Current Assets | $11.06M | $14.16M | $16.91M | $16.89M | $20.28M | $0 | $224K | $343K | $0 |
| Total Current Assets | $272.84M | $275.61M | $268M | $272.57M | $263.1M | $211.79M | $148.35M | $99.43M | $95.23M |
| Long-Term Assets | |||||||||
| Property, Plant & Equipment Net | $27.02M | $33.52M | $49.96M | $44.15M | $40.17M | $21.84M | $4.76M | $9.6M | $10.43M |
| Goodwill | $7.46M | $7.46M | $7.46M | $7.46M | $147.62M | $49.8M | $49.8M | $58.69M | $49.95M |
| Intangible Assets | $368.42M | $404.73M | $482.35M | $639.85M | $695.19M | $191.65M | $237.03M | $319.15M | $274.33M |
| Long-Term Investments | $0 | $0 | $0 | $2.64M | $29.29M | $19.38M | $2.78M | $0 | $0 |
| Deferred Tax Assets | $5.52M | $4.75M | $0 | $0 | $481K | $0 | $0 | $84K | $179K |
| Other Long-Term Assets | $2.29M | $1.89M | $3.14M | $405.98M | $50M | $0 | $0 | $393K | $298K |
| Total Long-Term Assets | $410.72M | $452.35M | $542.91M | $1.1B | $962.76M | $282.67M | $294.37M | $387.93M | $335.19M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $683.56M | $727.96M | $810.91M | $1.37B | $1.23B | $494.47M | $442.72M | $487.35M | $430.42M |
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts Payable | $10.93M | $23.69M | $23.04M | $36.7M | $16.91M | $4.42M | $8.21M | $8.37M | $5.38M |
| Short-Term Debt | $19.21M | $27.34M | $27.85M | $33.06M | $18.04M | $15M | $5.25M | $36.48M | $7.19M |
| Current Income Tax Payable | $0 | $3.87M | $4.75M | $2.57M | $8.14M | $2.43M | $2.03M | $2.66M | $1.31M |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $93.51M | $51.13M | $34.23M | $151.07M | $46.48M | $20.86M | $25.73M | $26.77M | $12.93M |
| Total Current Liabilities | $160.38M | $210.4M | $175.5M | $304.02M | $180.86M | $122.59M | $65.43M | $87.69M | $52.16M |
| Long-Term Liabilities | |||||||||
| Long-Term Debt | $278.95M | $308.29M | $367M | $385.01M | $339.64M | $173.38M | $189.58M | $157.61M | $162.3M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $433K | $564K | $1.21M | $2.25M | $133.52M | $3.36M | $3.96M | $8.78M | $9.33M |
| Other Long-Term Liabilities | $2.16M | $23.1M | $46.08M | $269.15M | $38.05M | $50.98M | $38.49M | $39.72M | $28.35M |
| Total Long-Term Liabilities | $294.73M | $331.95M | $414.3M | $656.41M | $511.21M | $227.72M | $232.03M | $207.32M | $200.78M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $455.11M | $542.35M | $589.79M | $960.43M | $692.07M | $350.31M | $297.46M | $295.01M | $252.93M |
| Stockholders' Equity | |||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $168M | $118M |
| Common Stock | $83K | $82K | $79K | $78K | $75K | $285.17M | $285.15M | $113.37M | $113.4M |
| Retained Earnings | -$334.93M | -$355.08M | -$321.54M | -$165.31M | -$6.6M | -$144.54M | -$139.82M | -$91.84M | -$56.49M |
| Comprehensive Income & Other | -$1.9M | -$2.57M | $794K | -$110K | $179K | $1.61M | -$65K | -$650K | $14K |
| Other Stockholders' Equity | $518.95M | $502.94M | $495.05M | $490.47M | $465.45M | $1.61M | -$65K | $170.81M | $120.58M |
| Total Equity | $184.1M | $147.94M | $173.59M | $325.24M | $458.92M | $142.24M | $145.27M | $192.34M | $177.49M |
| Minority Interest | $44.34M | $37.66M | $47.53M | $86.98M | $74.86M | $1.92M | $0 | $0 | $0 |
| Total Liabilities and Equity | $639.22M | $690.29M | $763.38M | $1.29B | $1.15B | $492.55M | $442.72M | $487.35M | $430.42M |
| Supplementary Data | |||||||||
| Total Debt | $311.35M | $335.63M | $394.85M | $418.07M | $357.68M | $188.38M | $194.83M | $196.51M | $170.98M |
| Net Debt | $260.11M | $294.05M | $357.88M | $387.88M | $313.75M | $101.54M | $152.05M | $191.56M | $155.2M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2018 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2018-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
| Operating Activities | ||||||||||
| Net Income | $27.27M | -$318K | -$121.2M | -$144.65M | $11.45M | $14.72M | $4.44M | -$34.11M | -$12.9M | -$22.37M |
| Depreciation & Amortization | $47.01M | $49.55M | $57.37M | $55.4M | $34.88M | $28.64M | $29.24M | $33.08M | $28.82M | $24.46M |
| Deferred Income Tax | -$909K | -$5.39M | -$2.38M | -$46.66M | -$9.76M | $0 | -$79K | -$432K | -$701K | -$475K |
| Stock-Based Compensation | $12.67M | $10.06M | $2.72M | $17.59M | $19.84M | $10.1M | $14.32M | $0 | $0 | $0 |
| Changes in Working Capital: | ||||||||||
| Accounts Receivable | -$916K | -$10.67M | $10.05M | -$17.67M | -$20.05M | $0 | -$12.13M | -$11.27M | -$217K | -$11.09M |
| Inventory | $8.57M | -$16.43M | -$5.99M | -$18.62M | $3.18M | $0 | $3.26M | -$5.73M | $10.65M | -$3.72M |
| Accounts Payable | -$19.81M | $0 | $0 | $0 | $0 | $0 | $12.15M | $5.18M | $3.04M | -$2.93M |
| Other Working Capital | -$1.68M | $15.32M | -$7.25M | $6.56M | $1.72M | $15.31M | -$422K | $1.17M | -$25.48M | $1.33M |
| Total Working Capital Change | -$13.84M | -$11.78M | -$3.18M | -$29.73M | -$15.14M | $15.31M | $2.85M | -$10.65M | -$12.01M | -$16.41M |
| Other Non-Cash Items | $1.77M | -$3.33M | $82.01M | $134.52M | -$18.28M | $3.02M | -$5.59M | $31.03M | $11.9M | $17.54M |
| Net Cash from Operating | $73.98M | $38.8M | $15.34M | -$13.54M | $22.99M | $71.8M | $45.19M | $18.92M | $15.11M | $2.75M |
| Investing Activities | ||||||||||
| Capital Expenditures | -$2.56M | -$1.01M | -$7.36M | -$1.48M | -$13.52M | -$16.58M | -$6.06M | -$2.12M | -$1.16M | -$6.36M |
| Acquisitions | -$686K | $0 | $34.67M | $0 | -$262.87M | $0 | $0 | -$51.46M | -$10.55M | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $23.97M | -$11.51M | -$114.96M | -$7.37M | -$3.92M | -$40K | -$6.61M | -$19.67M | -$4.64M |
| Net Cash from Investing | -$3.25M | $22.96M | $15.81M | -$116.44M | -$283.76M | -$20.5M | -$6.1M | -$60.19M | -$31.38M | -$11M |
| Financing Activities | ||||||||||
| Debt Repaid | $42.91M | $59.58M | $23.26M | -$59.62M | -$166.2M | $10M | $5.25M | $675K | -$155.75M | -$9.3M |
| Common Stock Issuance | $2.07M | $2.44M | $778K | $5.82M | $109.41M | $0 | $0 | $50M | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | -$367K | -$19.89M | -$7.85M | -$1.02M | -$2.4M | -$2.5M |
| Other Financing Activities | -$20.61M | $2.56M | -$4.17M | -$3.37M | -$1.88M | $317K | -$160K | -$17.06M | $0 | $0 |
| Net Cash from Financing | -$61.44M | -$54.58M | -$26.65M | $62.08M | $273.37M | -$29.57M | -$13.26M | $31.25M | -$6.64M | $6.8M |
| Forex Effect | $371K | -$2.56M | $629K | $521K | -$228K | $589K | -$160K | -$805K | -$1.43M | -$514K |
| Net Change in Cash | $9.66M | $4.62M | $5.13M | -$67.38M | $12.37M | $22.32M | $25.67M | -$10.82M | -$24.34M | -$1.96M |
| Supplementary Data | ||||||||||
| Operating Cash Flow | $73.98M | $38.8M | $15.34M | -$13.54M | $22.99M | $71.8M | $45.19M | $18.92M | $15.11M | $2.75M |
| Capital Expenditure | -$2.56M | -$1.01M | -$7.36M | -$1.48M | -$20.89M | -$20.67M | -$6.06M | -$7.44M | -$20.83M | -$6.36M |
| Free Cash Flow | $71.41M | $37.79M | $7.98M | -$15.02M | $2.1M | $51.13M | $39.13M | $11.48M | -$5.72M | -$3.61M |
| Cash at Beginning | $41.58M | $36.96M | $31.84M | $99.21M | $86.84M | $64.52M | $17.1M | $15.77M | $40.11M | $42.08M |
| Cash at End | $51.24M | $41.58M | $36.96M | $31.84M | $99.21M | $86.84M | $42.77M | $4.95M | $15.77M | $40.11M |